Apellis Pharmaceuticals
Platform of novel therapeutic compounds for the treatment of autoimmune diseases.
Launch date
Employees
Market cap
€4.2b
Enterprise valuation
€4.3b (Public information from Sep 2024)
Share price
$36.73 APLS
Waltham Massachusetts (HQ)
Authorizing premium user...